Objective: Utilization of pharmacogenomics data in clinical practice is a critical step towards individual and precision medicine. This is a cross-sectional study conducted by incorporating several variables as outlined in the survey report to assess and analyze the reasons or behaviors that could influence clinicians to use or not use pharmacogenomics.

Methods: In this study, we conducted a cross-sectional quantitative survey among primary physicians practicing in Kettering Health Network facilities. 1,201 invitations were sent out and 135 Physicians participated in the survey. Physicians were requested by email to participate in a survey containing 14 multiple choice questions regarding their understanding and beliefs regarding pharmacogenomics, as well as questions about specific professional details which were intended to explore how physician characteristics affected familiarity, and comfort and confidence in using pharmacogenomics data in patient care. Statistical Package for the Social Sciences (standard version 25) was used for statistical analysis and consent was obtained from all study participants through the survey link.

Results: The ratings of the familiarly, comfort, and confidence with pharmacogenetics were highly intercorrelated (r = 0.81-0.87).  Accordingly, we summed the three ratings to form a composite score of the three items; hereafter referred to as scale scores.  Possible scores ranged from 5 to 15, whereas actual scores ranged from 3 to 15 (Mean = 6.32, SD = 3.12). Scale scores were not statistically significantly correlated with age (r = 0.12, p < 0.17) or number of years in practice (r = 0.11, p < 0.22), and were only weakly (inversely) correlated with number of hours spent in patient care each week (r = -0.17, p < 0.05).

Conclusion: In our study, physicians who had some education in the field of pharmacogenomics were more likely to use pharmacogenomics data in clinical practice. We have further characterized that continuing medical education (CME), more than medical education or residency training significantly predicts familiarity, confidence, or comfort in using pharmacogenomics data. Therefore, pharmacogenomics should be integrated in the CME for practicing clinicians as well as graduate medical education.


  1. Jennifer L St Sauver, Suzette J Bielinski, Janet E Olson, Elizabeth J Bell, Michaela E Mc Gree, Debra J Jacobson, Jennifer B McCormick et al. Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality. Am J Med. 2016; 129(10):1093-1099.e1091. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27155109
  2. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011; 364 (12):1144-1153. DOI: 10.1056/NEJMra1010600
  3. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med. 2011; 78 (4):243-257. doi: 10.3949/ccjm.78a.10145
  4. Peter H. O’Donnell, Keith Danahey, Michael Jacobs, Nisha R. Wadhwa, Shennin Yuen, Angela Bush, Yasmin Sacro et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet. 2014; 166c (1):68-75. doi: 10.1002/ajmg.c.31385
  5. Weinshilboum RM, Wang L. Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clin Proc. 2017; 92(11):1711-1722. DOI: 10.1016/j.mayocp.2017.09.001
  6. P H O'Donnell, A Bush, J Spitz, K Danahey, D Saner, S Das, N J Cox et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012; 92(4):446-449. DOI: 10.1038/clpt.2012.117
  7. Suzette J Bielinski, Janet E Olson, Jyotishman Pathak, Richard M Weinshilboum, Liewei Wang, Kelly J Lyke, Euijung Ryu et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014; 89(1):25-33. doi: 10.1016/j.mayocp.2013.10.021
  8. Rohrer Vitek CR, Nicholson WT, Schultz C, Caraballo PJ. Evaluation of the use of clinical decision support and online resources for pharmacogenomics education. Pharmacogenomics. 2015; 16(14):1595-1603. DOI: 10.2217/pgs.15.100
  9. O Gottesman, S A Scott, S B Ellis, C L Overby, A Ludtke, J-S Hulot, J Hall et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin Pharmacol Ther. 2013; 94(2):214-217. DOI: 10.1038/clpt.2013.72
  10. C.A. Fernandez, C. Smith,1 W. Yang, R. Lorier, K.R. Crews, N. Kornegay, J.K. Hicks et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther. 2012; 92(3):360-365. doi: 10.1038/clpt.2012.95
  11. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther. 2012; 92(4):437-439. doi: 10.1038/clpt.2012.125
  12. Matthew T. Oetjens, Joshua C. Denny, Marylyn D. Ritchie, Niloufar B. Gillani, Danielle M. Richardson, Nicole A. Restrepo, Jill M. Pulley et al. Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics. 2013;14(7):735-744. doi: 10.2217/pgs.13.64
  13. J A Luzum, R E Pakyz, A R Elsey, C E Haidar, J F Peterson, M Whirl-Carrillo, S K Handelman et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming the challenges of real-world implementation. Clin Pharmacol Ther. 2013; 94(2):207-210. DOI: 10.1002/cpt.630
  14. J M Pulley 1, J C Denny, J F Peterson, G R Bernard, C L Vnencak-Jones, A H Ramirez, J T Delaney et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012; 92(1):87-95. DOI: 10.1038/clpt.2011.371
  15. Overby CL, Devine EB, Abernethy N, McCune JS, Tarczy-Hornoch P. Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians. J Biomed Inform. 2015; 55:249-259. DOI: 10.1016/j.jbi.2015.04.011
  16. Marc Hinderer, Martin Boeker, Sebastian A Wagner, Martin Lablans, Stephanie Newe, Jan L Hülsemann, Michael Neumaier et al. Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development. BMC Med Inform Decis Mak. 2017; 17(1):81.URI:https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-017-0480-y
  17. Elizabeth Cutting,a Meghan Banchero,a Amber L. Beitelshees,a James J. Cimino,b Guilherme Del Fiol,c Ayse P. Gurses,i,j,k Mark A. Hoffman et al. User-centered design of multi-gene sequencing panel reports for clinicians. J Biomed Inform. 2016; 63:1-10. doi: 10.1016/j.jbi.2016.07.014

Comments & Peer Review

Must Read